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Abstract
HIV-1 is taken up by immature monocyte derived dendritic cells (iMDDCs) into tetraspanin rich caves from which the virus
can either be transferred to T lymphocytes or enter into endosomes resulting in degradation. HIV-1 binding and fusion with
the DC membrane results in low level de novo infection that can also be transferred to T lymphocytes at a later stage. We
have previously reported that HIV-1 can induce partial maturation of iMDDCs at both stages of trafficking. Here we show
that CD45+ microvesicles (MV) which contaminate purified HIV-1 inocula due to similar size and density, affect DC
maturation, de novo HIV-1 infection and transfer to T lymphocytes. Comparing iMDDCs infected with CD45-depleted HIV-
1BaL or matched non-depleted preparations, the presence of CD45
+ MVs was shown to enhance DC maturation and ICAM-1
(CD54) expression, which is involved in DC:T lymphocyte interactions, while restricting HIV-1 infection of MDDCs.
Furthermore, in the DC culture HIV-1 infected (p24+) MDDCs were more mature than bystander cells. Depletion of MVs from
the HIV-1 inoculum markedly inhibited DC:T lymphocyte clustering and the induction of alloproliferation as well as limiting
HIV-1 transfer from DCs to T lymphocytes. The effects of MV depletion on these functions were reversed by the re-addition
of purified MVs from activated but not non-activated SUPT1.CCR5-CL.30 or primary T cells. Analysis of the protein
complement of these MVs and of these HIV-1 inocula before and after MV depletion showed that Heat Shock Proteins
(HSPs) and nef were the likely DC maturation candidates. Recombinant HSP90a and b and nef all induced DC maturation
and ICAM-1 expression, greater when combined. These results suggest that MVs contaminating HIV-1 released from
infected T lymphocytes may be biologically important, especially in enhancing T cell activation, during uptake by DCs in
vitro and in vivo, particularly as MVs have been detected in the circulation of HIV-1 infected subjects.
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Introduction
Dendritic cells (DC), located throughout the body, but in
particular in the male foreskin and the anogenital and cervical
mucosa, are susceptible to HIV-1 infection [1–3]. They are also
able to transfer HIV-1 to T lymphocytes, resulting in viral
dissemination [4]. This ability to transfer HIV-1 to T lymphocytes
is related to the function of DCs as antigen presenting cells, with
the efficiency depending on the functional state of the cells.
Immature DCs are highly endocytic; express low levels of major
histocompatibility complex (MHC)-I and MHC-II complexes and
co-stimulatory molecules but are considered to be poor processor
and presenters to T lymphocytes. Mature DCs however are
characterised by an up-regulation of surface expression of co-
stimulatory molecules CD40, CD80 and CD86 and de novo
expression of CD83 enabling efficient antigen presentation to and
activation of T lymphocytes [5,6]. Productive HIV-1 infection of
T lymphocytes is much more efficient in activated cells than
resting T lymphocytes [7,8]. Therefore maturation of DCs
following HIV-1 uptake is likely to be a key event in cell to cell
spread. Whilst one group has found that HIV-1 does not induce
maturation in either infected cells or uninfected bystanders [9],
our group and others showed that HIV-1 induces a partial
maturation of DCs [10–12]. Maturation genes were differentially
expressed to a greater degree in cells treated with viable compared
to non-viable virus indicating a role for replication over entry.
Furthermore, this partial maturation was shown to be a result of
p38 MAPK signalling [12]. The ability of DCs to form clusters
with T lymphocytes and the subsequent formation of an
immunological synapse is also important in HIV-1 transmission
and is dependent on the interaction between ICAM-1 (CD54) on
DCs and LFA-1 on CD4+ T lymphocytes [13] as evidenced by
impaired DC mediated HIV-1 transmission to T lymphocytes in
patients who lack LFA-1 on leukocytes [14]. Hence, the ability of
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HIV-1 to up-regulate the expression of adhesion and co-
stimulatory molecules on DCs as part of their maturation may
aid viral transfer to T lymphocytes and replication. HIV-1 transfer
from DCs to T lymphocytes occurs within a viral synapse. Viral
synapses are characterised by segregated supramolecular struc-
tures with a central cluster of envelope surrounded by a ring of
ICAM-1 [15–17] to induce DC:T lymphocyte adherence and
allow for viral transfer.
Both immature and mature DCs are able to transfer HIV-1 to T
lymphocytes by different mechanisms during 2 sequential phases
of uptake, the first following vesicular uptake and the second after
de novo infection of DCs transfer [18–21]. However mature DCs
formed DC:T lymphocyte conjugates more readily than immature
DCs even in the absence of specific antigen [22]. An additional
factor in HIV-1 transfer is the role of DC-derived microvesicle
(MV)-associated HIV-1 particles. Protein-laden MVs are released
from many different cell types, including the HIV-1 target cells T
lymphocytes and DCs. A significant fraction of these vesicles are
similar in size and density to HIV-1 virions, such that they
sediment with HIV-1 even when vigorous methods to purify the
virus are used [23]. In sucrose density gradient purified HIV
inocula from PBMCs the ratio of virions to MVs is 1:1–2 [24].
Vesicles and HIV-1 virions have similar, but not identical, protein
compositions [23–27]. These vesicles are primarily shedding
microvesicles (SMV) released from the cell surface, exosomes
released from late endosomes/multivesicular bodies by exocytosis
or apoptotic blebs (AB)s from dying cells, reviewed in [28]. The
signalling molecule CD45 is expressed on all hemopoietic cells and
is present in high concentrations on the MVs but specifically
excluded from HIV-1 virions. It can therefore be used to purify
viral stocks by removing contaminating vesicles [29–31]. Further-
more, the removal of vesicles by CD45-depletion is confirmed by
the removal of other cellular proteins from the HIV-1 preparation,
such as HLA-DR and actin [25].
In this study we have investigated the relative roles of HIV-1
and associated MVs on the maturation status of DCs and viral
transfer to T lymphocytes using HIV-1 inocula containing or
stripped of MVs. We have shown that MVs present within an
HIV-1 inoculum enhance MDDC maturation which in turn
induces more DC:T lymphocyte clusters and results in higher
levels of HIV-1 transfer to T lymphocytes. This induced
maturation limits the productive infection of monocyte-derived
DCs (MDDC). We propose that these MVs play a role in cell to
cell spread of HIV-1 in vitro and possibly in vivo.
Results
Microvesicles Restrict HIV-1 Infection of MDDC
Previous work from our laboratory showed partial maturation of
dendritic cells in response to HIV-1BaL, however we were unable
to rule out the role of MVs in non-viral replication dependent DC
maturation [10]. Therefore HIV-1BaL viral stocks with or without
the CD45+ MVs depleted were prepared as outlined by Bess et al
[23]. The SUPT1-CCR5-CL.30 cell line was infected with VSV-
G pseudotyped HIV-1pBaL, the CD45 contaminating MVs were
removed with microbeads and the virus preparation was
concentrated and purified further by centrifugation. The total
HIV-1 p24 concentration as determined by ELISA was compa-
rable for the HIV-1BaL(pellet) and HIV-1BaL(CD45
2) viruses.
Western blot analysis confirmed successful depletion of CD45
from the HIV-1BaL(CD45
2) stock.
MDDCs were infected with either HIV-1BaL(CD45
2) or HIV-
1BaL(pellet) at a MOI of 3 measured as TCID50. Levels of
productively infected cells were assessed by flow cytometry for
intracellular HIV-1 p24 antigen at 48 and 120 hours post infection
(Figure 1A and B). By 24 hours post infection, uptake of HIV-1
(p24 antigen) into vesicular/cave compartments of DCs have
dissipated [32]. Depletion of CD45+ MVs increased the infection
of MDDCs at both 48 and 120 hours (4.75+/21.5% SEM,
p,0.01 and 20.46+/211% SEM, p,0.05 respectively). The level
of HIV-1 proviral DNA was determined by Q-PCR and
confirmed the flow cytometry infection values with increased
infection of MDDCs at 120 hours when MVs were depleted
(4.8+/22% SEM at 48 hours and 22.7+/25.1% SEM at
120 hours, p,0.05, Figure 1C). These results indicated that the
CD45+ MVs limit the ability of the HIV-1 stock to productively
infect DCs. This effect was not mediated via SAMHD1 as levels
were similar in MDDCs treated with MVs from activated and
non-activated CD4+ lymphocytes by western blot and densitom-
etry (ratios of 0.9 and 0.9 respectively, compared to mock treated
MDDCs; Figure S1)
Removal of CD45+ Microvesicles Reduced the HIV-1
Induced Maturation of MDDCs
The susceptibility of DCs to become productively infected with
HIV-1 is related to the maturation status of the DCs [18]. We
therefore hypothesised that the increased infection rate in MDDCs
infected with HIV-1BaL(CD45
2) virus was a consequence of lower
maturation in these DCs compared to those infected with HIV-
1BaL(pellet). In order to show this, DCs were infected with HIV-
1BaL(pellet) or HIV-1BaL(CD45
2) virus for 48 hours and the level
of adhesion, co-stimulatory and other maturation markers was
determined by flow cytometry and confirmed by q-PCR (data not
shown). In agreement with our previously published work, HIV-
1BaL(pellet) induced partial up-regulation of CD80, CD83, CD86
and HLA-DR as well as a partial down regulation of DC-SIGN
and MR compared to a standard mixture of maturation inducing
cytokines and prostaglandins (Figure 2A and B). In view of the
importance of ICAM-1 in DC-T lymphocyte adhesion through
viral synapses [33] its expression following HIV-1BaL(pellet)
treatment was also examined and found to be elevated above
that induced by the maturation mix. In contrast, the removal of
Author Summary
Dendritic cells (DCs) are vital for immune recognition of
pathogens as they capture, internalise, degrade and
present foreign peptides to T lymphocytes. It is thought
that HIV-1 hijacks the DCs functions, such as migration and
maturation, to increase contact with the major target cell
CD4+ T lymphocytes leading to dissemination throughout
the body. Currently there is still some controversy over the
ability of HIV-1 to infect and mature DCs, which may be
due to differences in the inoculum used. Here we
examined the effect of contaminating microvesicles
(MVs) identified in HIV-1 preparations on HIV-1 modulation
of DC function. We show that when MVs are present with
HIV-1, the inoculum induces greater DC maturation and
adhesion probably via cellular HSP90a and b and viral nef
within the MVs. The functional consequences are reduced
de novo replication of HIV-1 but increased clustering with T
lymphocytes, resulting in increased T lymphocyte allopro-
liferation and HIV-1 transfer. As MVs are produced in HIV-1
susceptible cells and would be present in vivo due to HIV-1
induced cell death and hence are physiologically relevant,
these results also indicate that MVs present in HIV-1
inocula should be considered when assessing HIV:DC
interactions.
HIV Infection of DCs Is Affected by Microvesicles
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the CD45+ MVs resulted in a failure to up-regulate surface
expression of ICAM-1 and maturation markers on DCs including
CD80, CD83, CD86 and HLA-DR, as well as a lack of down-
regulation of CLRs compared to HIV-1BaL(pellet) treated cells
(Figure 2B), indicating that MVs in the HIV-1 preparation induce
some of the partial maturation.
To assess the kinetics of ICAM-1 up-regulation, the protein
expression was determined at 0, 16, 24, 48 and 96 hours post
infection by flow cytometry. We found that while ICAM-1
expression peaked at 16 hours post infection, the expression was
still above baseline levels at 48 hours post infection (Figure 2C).
When the MDDC population was divided into the infected
(p24+) and exposed but uninfected (p242) populations it became
apparent that within the HIV-1BaL(CD45
2) treated cells, matu-
ration was restricted to the p24+ productively infected cells and
very little bystander maturation of p242 cells was seen. This
contrasted with the HIV-1BaL(pellet) treated DCs which showed
increased CD83, CD86 and ICAM-1 expression in both infected
and bystander cells (Figure 2D). Thus removal of MVs from HIV-
1 preparations results in markedly reduced DC maturation and
ICAM-1 expression.
Addition of Microvesicles to HIV-1BaL(CD45
2) Restores
the Effects of HIV-1BaL(pellet)
To confirm that the differences induced by HIV-1BaL(pellet)
compared to HIV-1BaL(CD45
2) virus were a result of the MVs
that were removed, we next devised a MV replacement
experiment. The bead bound CD45+ MVs could not be used for
these replacement assays as the CD45 microbeads caused DC
maturation (data not shown). Additionally, it was not possible to
remove the CD45 beads from the depleted fraction without
damaging the MVs. We therefore generated MVs from
SUPT1.CCR5-CL.30 cells used for propagation of HIV-1 stocks
by stimulation with CD3 and CD28 antibodies for 3 days. The
supernatant was subsequently concentrated as for HIV-1BaL virus
stock generation. This method of activating SUPT1.CCR5-CL.30
cells resulted in similar cytopathic phenotypic changes to those
cells infected with HIV-1BaL. MVs from untreated SUPT1.CCR5-
CL.30 cells had no effect on HIV-1 induced DC maturation or
ICAM-1 expression (Figure 3A).
Once MV preparations were generated they were added back
to the HIV-1BaL(CD45
2) virus stock and then used to infect
MDDCs. HIV-1BaL(pellet) was used as a positive control and the
amount of MVs added was matched to the CD45 concentration of
the HIV-1BaL(pellet) virus (determined by western blot densitom-
etry, Table 1). In these experiments, the addition of isolated
MVs to the HIV-1BaL(CD45
2) virus resulted in increased
expression of adhesion, co-stimulatory, maturation markers and
CLRs on MDDCs while MVs alone did not induce maturation
(Figure 3A). There was a concentration dependent effect
(Figure 3B) as determined by CD83 and CD86 expression
(r = 0.9 and r = 0.87 respectively).
In addition to the enhanced maturation, adding back
MVs resulted in significantly less HIV-1 infection of MDDCs at
120 hours post infection (3.72+/21.1% SEM, p= 0.05, Figure 3B
and C). These results were further evidence that the maturation
status of DCs and level of infection closely correlate (CD83
expression versus p24; r =20.99).
In contrast to MVs from activated SUPT1.CCR5-CL30 cells,
MVs from primary CD4+ lymphocytes activated by anti-CD3 and
anti-CD28 antibodies induced significant maturation of MDDCs
alone, without accompanying HIV-1BaL(CD45
2) (Figure 3D).
In addition, exposure of primary blood myeloid BDCA1+ DCs
to HIV-1BaL(pellet) showed enhanced maturation (up-regulated
CD83) but this was diminished when they were exposed to
HIV-1BaL(CD45
2) and restored when MVs from activated
SUPT1.CCR5-CL.30 cells were added to HIV-1BaL(CD45
2)
(Figure 3E).
Clustering of HIV-1 Infected DCs with CD4+ Lymphocytes
ICAM-1 was markedly up-regulated in the MDDCs
infected with HIV-1BaL(pellet) compared to maturation mix or
Figure 1. HIV-1BaL(CD45
2) is more infectious in MDDCs than
HIV-1BaL(pellet). MDDCs were infected for 48 hr with HIV-1BaL(pellet)
or HIV-1BaL(CD45
2) at an MOI of 3 determined by TCID50, and assessed
for intracellular HIV-1 p24 antibody by flow cytometry and HIV-1
proviral DNA by Q-PCR. A) Representative dot plots of untreated and
HIV-1BaL(CD45
2) exposed DCs identifying infected (p24+ cells in box on
the right) and exposed but non-infected (p242) DCs at 120 hours. B)
The level of infection at 48 and 120 hours for both HIV-1BaL(pellet) and
HIV-1BaL(CD45
2) viruses by flow cytometry (mean +/2 SEM, n = 12,
*p,0.05 **p,0.01) and C) by Q-PCR (HIV-1 proviral DNA normalised by
albumin values) (mean +/2 SEM, n = 4, *p,0.05).
doi:10.1371/journal.ppat.1003700.g001
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Figure 2. HIV-1BaL(CD45
2) induces less maturation than HIV-1BaL(pellet). MDDCs were exposed to high titre HIV-1BaL(pellet), HIV-
1BaL(CD45
2) at a MOI of 3 or a potent maturation cocktail for 48 hours and expression of maturation determined by flow cytometry. A)
HIV Infection of DCs Is Affected by Microvesicles
PLOS Pathogens | www.plospathogens.org 4 October 2013 | Volume 9 | Issue 10 | e1003700
HIV-1BaL(CD45
2) virus (Figure 2B). This was further supported
by investigating the expression in the infected populations and
showing increased expression in p24+ MDDCs compared to p242
MDDCs for both virus stocks (Figure 2D). The functional effects of
increased ICAM-1 expression include increased and more stable
DC:T lymphocyte conjugates so we examined this by developing a
DC:T lymphocyte clustering assay using flow cytometry. Optimal
conditions were obtained by co-culturing immature or mature
MDDCs with autologous CD4+ T lymphocytes for 45 minutes at a
ratio of 5 T lymphocytes:1 DC. The cells were then labelled with
CD1a (DC marker) and CD3 (T lymphocyte marker) antibodies.
Within the DC population the proportion of cells that were also
positive for CD3 were considered to be DC:T lymphocyte clusters
(gating strategy Figure 4A and B). This resulted in 44.5+/22.9%
SEM of mature DCs forming detectable clusters with T
lymphocytes compared to 13.2+/21.3% SEM of immature DCs
forming clusters with T lymphocytes (Figure 4B). Results were
validated by comparison between mature DCs involved in clusters
by flow cytometry and by counting of those in contact with T
lymphocytes using confocal microscopy (correlation .90%, data
not shown).
DCs were then infected with either HIV-1BaL(pellet) or HIV-
1BaL(CD45
2) virus for 48 hours and co-cultured with autologous
CD4+ T lymphocytes. The percentage of DCs that clustered with
CD4+ T lymphocytes was significantly different between the two
virus stocks (p,0.02). The HIV-1BaL(CD45
2) treated DCs, which
showed very little up-regulation of co-stimulatory markers or of
ICAM-1, had levels of clustering with CD4+ lymphocytes (17.2+/
22.9% SEM) similar to the untreated negative control DCs. In
contrast, the HIV-1BaL(pellet) treated DCs with higher ICAM-1
and co-stimulatory marker expression showed an increased cluster
formation with CD4+ T lymphocytes (30.44+/24.8% SEM),
similar to mature DCs (Figure 4C).
After defining infected and bystander MDDCs separately,
significantly higher clustering was seen in the p24+ DCs than in
p242 DCs for HIV-1BaL(pellet) (Figure 4D). Finally, blocking
experiments with an antibody to ICAM-1 which reduced
clustering to baseline levels, indicated that the elevated clustering
seen with HIV-1BaL(pellet) treated MDDCs was due to ICAM-1
expression on DCs (Figure 4E). Thus, elevated ICAM-1 expression
on HIV-1BaL(pellet) treated MDDCs results in greater DC:T
lymphocyte cluster formation than in HIV-1BaL(CD45
2) treated
MDDC.
Microvesicles Enhance HIV-1 Infected DC Mediated
Allogeneic Proliferation of T Lymphocytes
Next, the effects of differential DC maturation by the two HIV-
1BaL stocks upon T lymphocyte proliferation were examined.
MDDCs were exposed to HIV-1BaL(pellet) or HIV-1BaL(CD45
2)
virus for 48 hours and then added to CFSE labelled allogeneic
PBMCs from HIV-1 seronegative subjects at a ratio of 1 DC:10
PBMC and co-cultured for a further 5 days. Following culture,
cells were assessed for proliferation by flow cytometry. CD4+ T
lymphocyte and MDDC populations were identified by size gating
and the level of proliferation was assessed by CFSE dilution
(Figure 5A). The percentage proliferation for each treatment was
determined by normalising the CFSE dilution percentage to the
percentage of live cells for both the PBMC and the MDDC
populations. The values were then added to account for all CD4+
T lymphocytes present (Figure 5B). Immature and mature
MDDCs co-cultured with CFSE labelled PBMC were used as
negative and positive controls respectively (7.1+/21.5% SEM,
10.7+/20.9% SEM) (Figure 5B). HIV-1BaL(pellet) exposed DCs
induced greater proliferation (36.2+/27.2% SEM) of CD4+ T
lymphocytes compared to mature DCs, whilst HIV-1BaL(CD45
2)
exposed DCs were significantly impaired in their capacity to
induce T lymphocyte proliferation (4.98+/20.5% SEM) com-
pared to mature and HIV-1BaL(pellet) exposed DCs (p = 0.01 and
p= 0.05 respectively).
Microvesicles Enhance DC Mediated HIV-1 Transfer
As DCs are very efficient at transferring HIV-1 to T
lymphocytes, we investigated the capacity of MDDC infected
with the two different virus stocks to induce T lymphocyte
activation and to transmit virus to T lymphocytes. MDDCs were
infected with either HIV-1BaL(pellet) or HIV-1BaL(CD45
2) virus
for 48 hours and added to resting autologous CD4+ T lympho-
cytes for up to 96 hours. The levels of CD69 expression on CD4+
T lymphocytes, as a marker for T lymphocyte activation
(Figure 6A), and the percentage of p24+ T lymphocytes
(Figure 6B) was assessed over time. Consistent with their effects
on DC maturation, only the HIV-1BaL(pellet) exposed DCs were
able to induce activation of CD4+ T lymphocytes at 24 and
48 hours post co-culture.
CD4+ lymphocytes co-cultured with HIV-1BaL(pellet) exposed
MDDCs resulted in higher and more rapid kinetics of infected
CD4+ lymphocytes than when co-cultured with HIV-1BaL(CD45
2)
exposed MDDCs. Thus suggesting that DC maturation induced
by MVs as well as virus in HIV-1BaL preparations acts to enhance
HIV-1 transmission.
Characterisation of Microvesicles
We next characterised the MVs in the HIV-1 and activated
SUPT1.CCR5-CL.30 stocks. Initially, key candidate proteins
present in MVs from the HIV-1BaL(pellet) and the MVs obtained
from CD3/CD28 activated and non-activated SUPT1.CCR5-
CL.30 cells were investigated by Western blot and compared to
HIV-1BaL(CD45
2), parent SUPT1.CCR5-CL.30 cells as well as
the anti-CD45 bead bound HIV-1BaL preparation (Figure 7 and
Table 2). Both HIV-1 and MV preparations were positive for the
tetraspanin/exosome marker CD81 but CD9 and Alix were
undetectable. In addition, HIV-1BaL(CD45
2), HIV-1BaL(pellet)
and activated SUPT1.CCR5-CL.30 MVs contained the histone
marker H2A indicative of ABs. Heat shock proteins (HSP) 90a
and 90b (AB1) were also detected in both the viral and MV
preparations (Figure 7).
To fully characterize the protein complement of the MVs from
the two HIV-1 inocula and also the anti-CD45 bead bound
Representative histograms for CD83 and CD86 shown (isotype grey tint, immature solid grey line, HIV-1BaL(CD45
2) dashed line, HIV-1BaL(pellet)
dotted line and mature solid black line). B) The levels of surface maturation marker expression with flow cytometry MFI results expressed as a ratio of
normalised to untreated (mock/immature) controls as log (2) fold change (mean +/2 SEM, n = 12, *p,0.05 **p,0.01). C) Kinetics over time of ICAM-1
expression determined by flow cytometry MFI for HIV-1BaL(pellet) treated MDDCs (mean +/2 SEM, n= 3). D) Productively infected MDDCs are more
mature than uninfected MDDCs for both virus stocks. Infected cells were identified by p24 antigen staining and the expression of CD83, CD86 and
ICAM-1 was compared to that for the HIV-1 exposed uninfected cells. Representative histograms for the markers of p24+ (dashed line) and p242
(dotted line) compared to isotype control (grey tint) for HIV-1BaL(pellet) and HIV-1BaL (CD45
2). Bar graphs delineating the expression of normalised
maturation and co-stimulatory marker expressed as log (2) fold change to mock treated cells (mean +/2 SEM, n = 5, *p,0.05).
doi:10.1371/journal.ppat.1003700.g002
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Figure 3. Addition of microvesicles to HIV-1BaL(CD45
2) restores MDDC maturation. MDDCs were either treated with HIV-1BaL(pellet), HIV-
1BaL(CD45
2) alone, CD3/CD28 activated MVs (20 ml/3.56105 cells) alone or HIV-1BaL(CD45
2) with the addition of CD3/CD28 activated MVs for
HIV Infection of DCs Is Affected by Microvesicles
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material compared to those from activated and non-activated
SUPT1.CCR5-CL.30 cells we separated the protein bands by gel
electrophoresis and subjected them to Tandem Mass Spectrom-
etry. After filtering for non-human contaminating proteins present
in the fetal calf serum, 266 proteins with.0.01% share of the total
were detected in HIV-1BaL(pellet), 255 in HIV-1BaL(CD45
2), 274
in the anti-CD45 bead bound preparation, 462 in MVs from
activated SUPT1.CCR5-CL.30 and 143 from non-activated
SUPT1.CCR5-CL.30 MVs. The key proteins characteristic of
MVs which were identified are shown in Tables 3 and 4. These
included a-enolase, pyruvate kinase, actin and actin related
proteins, the tetraspanins, CD9 and CD81, and several heat
shock proteins especially HSP90a and b. HSP90a and HSP90b,
were the only cellular proteins present in concentrations of
.0.01% which were likely to act as DC maturation stimuli in
HIV-1BaL(pellet) and activated SUPT1.CCR5-CL.30 MVs and
were present at high concentrations in HIV-1BaL(pellet) (0.32%
and 0.20% of peptide spectrum IDs respectively) and in the
activated SUPT1.CCR5-CL.30 MVs (0.40% and 0.25% respec-
tively) (Table 4). They were also in the top 20 of the 200–400
identified proteins. HSP90a and b were present at 3 fold and 6
fold higher concentrations respectively in MVs from activated than
in non-activated uninfected SUPT1.CCR5-CL.30 cells, By mass
spectrometry there was little difference in HSP90a concentrations
in HIV-1BaL(pellet) and HIV-1BaL(CD45
2) but HSP90b appeared
to be present at lower levels in HIV-1BaL(pellet) (0.20%) than after
depletion of MVs with CD45 antibody bound beads (0.63%)
(Table 4), although this was not supported by western blot and
densitometry (Figure 7). Here both HSP90a and b were evenly
distributed between HIV-1BaL(pellet) and HIV-1BaL(CD45
2)
inocula and both were present on CD45+ beads. However both
were markedly increased, especially HSP90a in MVs from
activated verses non-activated SupT1 cells. HSP70/71 were
present at very low concentrations in all preparations (by MS).
The HIV-1 accessory protein nef was present in HIV-
1BaL(pellet) (at lower levels than gag or env), but completed
depleted from HIV-1BaL(CD45
2) virus. However, Gag/pol and
env peptides were concentrated 1.5 to 3 fold in HIV-1BaL(CD45
2)
compared to HIV-1BaL(pellet) (Table 4). Direct comparison of the
levels of HIV-1 proteins concentrated on the anti-CD45 beads
showed a rank order of gag/pol (mean 2.16% share), env (mean
0.12%), nef (mean 0.033%), vpr (0.015%).
To directly examine the effect of HSPs 90a and b and nef on
MDDC maturation, graded concentrations of recombinant HSP
90a (Figure S2) and 90b and of nef were added to MDDCs
(Figure 8A and B). Each alone induced maturation and ICAM-1
expression in a concentration dependent fashion. HSP90b was
more potent than HSP90a (minimal effective concentrations 2.5–
5 nM, significant at 25 nM for HSP90b and for HSP 90a effective
at 25 nM, significant at 50 nM). The lowest effective concentra-
tion of nef was 10 nM (Figure 8B).
The combination of recombinant nef at its lowest effective
concentration (10 nM) with HSP90b at a concentration (0.5 nM)
tenfold below its minimum effective concentration (5 nM)
enhanced maturation above nef alone, especially for CD80
(Figure 8C). Thus, MVs contain viral and cellular proteins that
are capable of potent stimulation of DC maturation and ICAM-1
expression.
Discussion
Purification of HIV-1 preparations released from infected T
lymphocytes by removal of the contaminating MVs can be
achieved by CD45 depletion [23,25,30]. In this paper we have
described experiments using HIV-1 inocula with and without
depletion of CD45+ MVs and then restoration of MVs from
activated uninfected SUPT1.CCR5-CL.30 or primary T cells to
investigate the biological role of MVs in HIV-1 uptake by and
infection of MDDCs. When compared, we observed that HIV-
1BaL depleted of MVs infected DCs to a greater extent than HIV-
1BaL containing MVs. However, HIV-1 depleted of MVs induced
much less MDDC maturation, ICAM-1 expression and clustering
with CD4+ T lymphocytes than HIV-1 containing MVs. This
should also be applicable in the tissue microenvironment in vivo.
Several HIV-1 restriction factors have been described for
DCs, including the constitutively expressed APOBEC3G [34],
SAMHD1 [35] and the HIV induced interferon stimulated genes
[36]. Our finding that MVs within the viral inocula restrict HIV-1
infection of DCs may reflect a further mechanism by which DCs
are able to control viral infection, or more importantly, their
induction of partial maturation may facilitate viral transfer to
CD4+ lymphocytes. It has been well documented that immature
MDDCs are more HIV-1 susceptible than mature MDDCs [37–
40] due to differences in CCR5 expression which is required for
HIV-1 fusion [41] as well as reverse transcription and/or post-
integration blocks [42,43]. The presence of MVs in the inoculums
resulted in increased maturation (but not SAMHD1 levels) of both
productively infected and bystander DCs. This enhanced matu-
ration, particularly in the bystander cells may explain the lower
levels of HIV-1 infection in DCs infected with HIV-1BaL(pellet).
In this study we show that productively infected DCs are more
mature than exposed bystander cells, confirming our previous
48 hours. To calculate the MV ‘inoculum’ the CD45 concentration of the MVs preparation was matched to the CD45 concentration of the HIV-
1BaL(pellet) stock (see Table 1). A) The expression of maturation markers was determined by flow cytometry and compared to the maturation seen
with the HIV-1BaL(pellet) stock (mean +/2 SEM, n= 3, *p,0.05 **p,0.01). B) The expression of CD83 and CD86 was assessed and there was a positive
correlation between amount of MVs added and the level of maturation seen in HIV-1 exposed MDDCs (mean +/2 SEM, n = 3, CD83: p = 0.78, r = 0.9
and CD86: p = 0.27, r = 0.87). The level of p24+ cells was also measured by flow cytometry. C) The proportion of HIV-1 infected MDDCs at 120 hours
was reduced by addition of MVs to the HIV-1BaL(CD45
2) inoculum (mean +/2 SEM, n= 3, *p,0.05). D) MVs from anti CD3/CD28 activated primary T
lymphocytes also induce MDDC maturation. MDDCs (0.56106 cells/mL) were treated with MVs from CD3/CD28 activated or non-activated primary T
lymphocytes at the same concentration as in panel A for 48 hours and expression of CD80, 83 and 86 measured by flow cytometry (mean +/2SEM,
n = 3, *p,0.05, **p,0.01 compared to mock or, where bracketed, activated MVs are compared to non-activated MVs). E) HIV-1BAL(pellet) and
MVs+HIV-1BAL(CD452) also induce maturation of primary blood myeloid DCs. Blood myeloid BDCA1 DCs (0.56106 cells/mL) were isolated from blood
and exposed to maturation mix, HIV-1BAL(pellet), HIV-1BAL(CD45
2) and HIV-1BAL(CD45
2)+MVs from activated SUPT1.CCR5-CL.30 cells at similar
concentrations to panel A. CD83 expression was measured by flow cytometry. Representative histogram of three separate experiments.
doi:10.1371/journal.ppat.1003700.g003
Table 1. Western blot densitometry of HIV-1 preparations.
HIV-1BaL
(pellet)
HIV-1BaL
(CD452)
HIV-1BaL
(CD45+) bead
Band
intensity
100+/20.01 6.343+/20.04 93.363+/20.41
Net intensity normalised to HIV-1BaL (pellet) +/2 SE n = 3. Image J analysis.
doi:10.1371/journal.ppat.1003700.t001
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findings that the maturation was a result of HIV-1 replication, as
well as exposure [10,11]. The role of HIV-1 replication in DC
maturation was strengthened by the observation that HIV-
1BaL(CD45
2) productively infected DCs exhibited some matura-
tion. MVs present in the HIV-1BaL(pellet) preparation must have a
role in uninfected bystander DC maturation as their removal
eliminated this effect. The greater maturation seen in the
productively infected DCs with HIV-1BaL(pellet) compared to
HIV-1BaL(CD45
2) suggested an additive effect from the MVs. The
use of two different HIV-1BaL inocula may contribute to an
understanding of the different routes of entry of HIV-1 into DC.
At early time points post infection HIV-1 and MVs induce
maturation of infected DC as well as uninfected bystander DC due
to vesicular uptake (into ‘caves’ and late endosomes). At later time
points (.48 hpi) however, the effects of replicating HIV-1 on DC
maturation may dominate. It is of note that we have assumed in
this paper that HIV-1 p242 DCs were uninfected. This is probably
true of the majority of DCs, although a small proportion of these
cells will be in the early stages of infection but do not yet express
HIV-1 DNA+ p24 antigen at detectable levels. Furthermore while
Figure 4. HIV-1 infection enhances clustering of DCs with autologous CD4+ T lymphocytes. MDDCs were either untreated or exposed to
HIV-1BaL(pellet), HIV-1BaL(CD45
2) (MOI 3) or a potent maturation cocktail for 48 hours and co-cultured with autologous CD4+ T lymphocytes at a ratio
of 5 T lymphocytes:1 DC for 45 minutes. A) Representative dot plot of the flow cytometry gating strategy for MDDC selection by FSC and SSC. B)
Clusters were identified as double positive for CD3 (T lymphocyte marker) and CD1a (DC marker). Representative dot plots are shown. C) The
percentage of DC clusters following treatment (mean +/2 SEM, n = 10, *p,0.05 **p,0.01). D) DC:CD3+ cell clusters were identified in the p242 and
p24+ fractions of the co-culture and compared by box and whisker plots for the HIV-1BaL(pellet) virus (mean +/2 SEM, n = 10, **p,0.01). E) Cluster
formation following addition of neutralising antibody to ICAM-1 (mean +/2 SEM, n= 3, *p,0.05).
doi:10.1371/journal.ppat.1003700.g004
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CD14+ monocytes are commonly used as a source of in vitro
MDDCs, the use of MDDCs in this study is strengthened by the
observations that in vivo equivalent cells in both mice [44,45] and
recently in humans can be generated during physiological stress
[46,47]. Nevertheless we also found similar effects of HIV-1
inocula with and without MVs on primary blood BDCA1+
myeloid DCs.
The adhesion molecule ICAM-1 was investigated due to its role
in immunological and viral synapse formation [48] and was shown
to be expressed to a greater extent than other maturation and co-
stimulatory markers examined by HIV-1BaL(pellet) compared to
matured DCs. This supports the findings that DC subsets
expressing higher levels of ICAM-1 transmit HIV-1 more
efficiently [49]. The functional consequences of DC maturation
and ICAM-1 expression were assessed using a novel flow
cytometry based assay to assess DC:T lymphocyte clustering
interactions. The results showed that HIV-1BaL(pellet) treated DCs
cluster with T lymphocytes to a greater extent than with immature
DCs although less than matured DCs. Furthermore productively
infected cells cluster more than uninfected bystander DCs which
were exposed to the inoculum. Previous work has shown that
HIV-1 viral protein nef increases the capacity of DCs to form
clusters with allogeneic CD4+ T lymphocytes which increased
immunological synapse formation [50,51] and blocking ICAM-1
has been shown to decrease HIV-1 transfer [13,14]
As well as different levels of DC maturation seen when cells
were treated with HIV-1BaL(pellet) or HIV-1BaL(CD45
2), corre-
sponding rates of T lymphocyte proliferation and HIV-1 transfer
were observed. DCs treated with HIV-1BaL(pellet) led to greater
CD4+ and CD8+ T lymphocyte proliferation than those treated
with HIV-1BaL(CD45
2). In addition, HIV-1BaL(pellet) led to
transfer of HIV-1 to both activated and resting CD4+ T
lymphocytes, while HIV-1BaL(CD45
2) was unable to activate
contacting CD4+ T lymphocytes and was only able to be
transferred to activated CD4+ T lymphocytes, probably due to
decreased ICAM-1 expression and clustering. This indicated a
significant role for infected and especially bystander DC matura-
tion due to presence of MVs, on HIV-1 transfer. These results
together are important as, until now, it has not been possible to
determine the individual roles of maturation and infection on the
spread of HIV-1 from DCs to T lymphocytes.
The viral inoculum in vivo (e.g. in semen or blood) is derived
from lysed infected CD4+ lymphocytes and therefore likely to
contain MVs, so this is a more physiologically relevant viral
inoculum. HIV-1 infected activated T lymphocytes burst release
HIV-1 [52,53] which also releases cell debris and MVs. Such MVs
containing HIV-nef have been identified and quantified in vivo in
(ultracentrifuged) plasma from HIV infected [54,55].
Our results show that in vitro a low proportion of HIV-1 infected
DCs, if accompanied by maturation, is more important in virus
Figure 5. HIV-1 exposed MDDC stimulate PBMCs to proliferate. MDDCs exposed to HIV-1BaL(pellet) or HIV-1BaL(CD45
2) for 48 hours were co-
cultured with allogeneic PBMC at a ratio of 1 DC:10 PBMC for 5 days. Proliferation was determined by CFSE dilution. The cells were stained for CD4+ T
lymphocytes and analysed by flow cytometry. A) Representative dot plots of CD4+ T lymphocytes for each treatment are shown. B) The bar graph
compares the proliferation between each treatment determined by adding the percentage proliferation normalised to live cell number of the CD4+
lymphocyte population and the MDDC population (mean +/2 SEM, n= 3, *p = 0.05 **p= 0.01).
doi:10.1371/journal.ppat.1003700.g005
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transfer to T lymphocytes than high levels of DC infection without
maturation (Figure 9). Brenchley et al described the systemic
activation of the immune system in relation to HIV-1 immuno-
pathology [56] whereby CD4+ T lymphocytes are constantly
activated by leaky gut products which support HIV-1 replication
and lead to significant CD4+ T lymphocyte death [57]. It was
shown that circulating LPS was significantly increased in
chronically HIV-1 infected individuals and in simian immunode-
ficiency virus (SIV)-infected rhesus macaques, while this was not
seen in non-pathogenic SIV infection of sooty mangabeys [58]. By
analogy MVs released in parallel with HIV-1 should also induce
DC activation of CD4+ T lymphocytes in vivo and this may
contribute to HIV-1 replication and spread.
Recent studies have shown that many virally infected cells
secrete MVs, including vaccinia virus [59], hepatitis C [60] and
Epstein Barr virus (EBV) [61,62]. The analysis of the protein
complement of the MVs present in the anti-CD45 bead bound
and activated SUPT1.CCR5-CL.30 preparations, especially by
Mass Spectrometry, detected candidate maturation inducing
proteins: the HSPs 90a and b, and HSPs 70/71 (the latter at
very low levels) and the HIV-1 protein nef [63].HSPs function as
chaperone proteins with varied cellular locations (see review: [64])
and have been shown to act as a source of antigen and may play a
role in the transfer of peptides to APCs when released into the
extracellular milieu in exosomes [65,66]. When expressed on the
cell-surface HSPs are capable of activating the immune system in
vivo [67,68]. Several heat shock proteins (HSPs 60, 70/71, 96) have
been reported to induce maturation or activation of DCs to
variable extents, independently of lipopolysaccharide,, via NFkB
and the MAPK pathway [63,69–73]. Here we have shown that
HSPs 90a and b, are the major cellular HSPs expressed in MVs
and are fairly evenly distributed between MVs and MV depleted
HIV. Both purified recombinant HSP90a and b induce matura-
tion of MDDCs alone with HSP90b being the most potent.
Nef was also detected in MVs but depleted in the MV stripped
HIV inoculum. Pure reombinant nef was a potent inducer of
MDDC maturation. Nef has previously been shown to be secreted
in exosomes and induce bystander cell effects, [74] and to be taken
up by DCs and induce IL-12 secretion and clustering with T
lymphocytes. Effects on DC maturation and ICAM-1 expression
were not studied [51]. In our experiments a combination of both
proteins induced higher levels of DC maturation/ICAM-1
expression together than either alone. Nevertheless MVs from
uninfected activated SUPT1.CCR5-CL.30 cells or primary T
lymphocytes containing only HSP90a/b but at high concentra-
tions, could substitute for the MVs from infected cells, containing
both HSP90a/b, and nef. Thus both HSP90a/b are responsible
for the effect MVs derived from uninfected activated primary T
and SUPT1.CCR5-CL.30 cells in enhancing maturation of
MDDCs.
The complexity of the HIV-1 and MV effects on DCs is
dissected into 4 scenarios in panels A and B of Figure 9. In panel A
Figure 6. The presence of microvesicles enhances DC-stimulated CD4+ T lymphocyte activation and subsequent transfer of HIV-1.
A) MDDCs treated with HIV-1BaL(pellet) or HIV-1BaL(CD45
2) at (MOI 3) for 48 hours were co-cultured with unstimulated autologous CD4+ T
lymphocytes. The expression of CD69 on T lymphocytes was determined by flow cytometry at 24, 48, 72 and 96 hours post T lymphocyte addition
(mean +/2 SEM, n = 3, *p,0.05). B) The level of infection of T lymphocytes was determined by gating on CD3+ cells (to exclude DCs) followed by p24
staining determined at 24, 48, 72 and 96 hours post T lymphocyte addition (mean +/2 SEM, n = 3, *p,0.05).
doi:10.1371/journal.ppat.1003700.g006
HIV Infection of DCs Is Affected by Microvesicles
PLOS Pathogens | www.plospathogens.org 10 October 2013 | Volume 9 | Issue 10 | e1003700
the whole MDDC culture is exposed to an inoculum of HIV
virions, containing HSP90a/b, and MVs, containing HSP90a/b
and nef, leading to maturation of both infected and uninfected
bystander DCs (which are the majority). Additionally infected DCs
produce endogenous nef, possibly explaining the higher degree of
maturation. In panel B the whole MDDC culture is exposed to
HIV containing (a lower dose of) HSP90a/b but not nef, which is
insufficient to induce maturation in bystander DCs. Exogenous
MVs from activated uninfected T lymphocytes, bearing HSP90a/
b, are sufficient to restore the maturing effect of the inoculum. In
the infected MDDCs the production of endogenous nef in the
infected DCs probably combines with exogenous HSP90a/b, to
induce a low degree of maturation. These proteins may induce
signalling either through the Vav pathway (for nef) or plasma
membrane TLR2/4 (for HSPs) [51].
In conclusion, in vitro DC maturation and ICAM-1 up-
regulation is induced by MVs and HIV-1 exposure in all cells of
the culture and by HIV-1 replication as well as exposure to MVs
in infected DCs. In turn this maturation and adhesion molecule
up-regulation induces greater cluster formation and activation of
CD4+ T lymphocytes and subsequent transfer of HIV-1. Hence
the biological role of MVs in HIV-1 emerging from lysing CD4+
lymphocytes needs to be considered during DC infection in vitro
and in vivo. Activation of T lymphocytes in vivo may contribute to
the progressive immunodeficiency of HIV disease. Conversely
exposure of uninfected bystander DCs in vivo could lead to
Figure 7. Western blot characterisation of HIV-1, microvesicles and parent cell line preparations. 30 mg of protein from MDDCs,
SUPT1.CCR5-CL.30, bead bound HIV-1BaL(CD45
+), HIV-1BaL(CD45
2), HIV-1BaL(pellet), non-activated MV and activated MV preparations were compared
for the expression of A) CD45, B) Alix, C) CD81, D) H2A, E) HSP90a F) HSP90b by western blot using SDS-page gel, nitrocellulose membrane and
developed by chemiluminescence.
doi:10.1371/journal.ppat.1003700.g007
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endosomal then cytosolic uptake of MVs containing nef and
HSP90a/b, maturation of DCs and induction of CD8 lymphocyte
responses to nef, which is disproportionately recognised as a target
HIV protein.
Materials and Methods
Cell Culture
MDDCs were generated from CD14+ monocytes isolated from
peripheral blood mononuclear cells (PBMC) of anonymous blood
donors from the Australian Red Cross Blood Service, Sydney
using CD14 magnetic beads (Miltenyi Biotech; Gladbach,
Germany) as described previously [10].
When required, MDDC were matured for 48 hours in
maturation mix consisting of (v/v) final concentration 50 pg/mL
IL-1b (R&D Systems; Minneapolis, MN, USA), 5 U/mL IL-6
(R&D Systems), 50 pg/mL TNF-a (R&D Systems) and 5 ng/mL
PGE2 (Sigma; Milwaukee, WI, USA) in 0.1% (w/v) bovine serum
albumin (BSA, Sigma) PBS.
CD4+ T lymphocyte isolation (97% purity) was performed using
magnetic beads (Miltenyi Biotech) according to the manufacturer’s
protocol.
Primary blood myeloid DCs were isolated from PBMCs
collected from whole blood, using a negative selection magnetic
bead myeloid DC isolation kit (Miltenyi), as per manufacturer’s
instructions. Isolated mDCs were cultured at 16106 cells/mL in
RF10 (RPMI supplemented with 10% FCS and no cytokines) and
collected at 24 h post treatment.
Phenotype/purity was checked by Flow cytometry. Stained with
Live/Dead Aqua (Invitrogen), Lin marker (BD), HLA-DR
(Biolegend), BDCA-1 (Miltenyi) and BDCA-3 (Miltenyi). Matura-
tion was checked by staining with Live/Dead, HLA-DR, BDCA3,
CD83 (BD) and CD86 (BD). Cells were gated by size, Live, and
HLA-DR+ before gating on BDCA-3+ and BDCA-32 (‘‘BDCA-
1’’). CD83 and CD86 expression was analysed on the separate
BDCA-1/BDCA-3 populations.
Recombinant Proteins
Recombinant HSP90a and b free of LPS, were purchased
from Abcam, UK (at 2.7 mg/mL and 1.7 mg/mL respectively)
and recombinant nef from BioAcademia Inc. Japan (at 0.48 mg/
mL)
Virus and Microvesicle Preparations
HEK293T cells (Human Embryonic Kidney cells, NIH AIDS
Research and Reference Reagent Program) were transfected with
pWT/BaL (NIH AIDS Research and Reference Reagent Program,
contributed by Dr. Bryan R. Cullen) and pHEF-VsV-g (NIH
AIDS Research and Reference Reagent Program, contributed by
Table 2. Western blot characterisation of HIV-1 and microvesicle preparations.
MDDC SUPT-1 Bead HIV-1BaL (CD45+) HIV-1BaL (CD452) HIV-1BaL (pellet) Vesicles (activated) Vesicles (non-act)
CD45 +++ ++ ++ 2 + + +
Alix + 2 2 2 2 2 2
CD81 + 2 + + + ++ +
H2A 2 2 2 ++ ++ + 2
HSP90a ++ ++ + + + + 2
CD9 + ++ 2 2 2 2 2
CD11a + 2 2 2 2 2 2
CD40 +++ + 2 2 2 2 2
H3 2 2 + + 2 2 2
CD40L + + + + + 2 2
TNF-ay 2 2 2 2 2 2 2
HSP60 + + 2 2 2 2 2
HSP70j 2 2 2 2 2 2 2
+++ high protein expression, 2 below detection limit.
ypositive in PBMCs,
jpositive in transfected lysate.
doi:10.1371/journal.ppat.1003700.t002
Table 3. Characteristic microvesicle specific proteins present in anti-CD45 bead bound HIV-1 inoculum and SUPT1.CCR5-CL.30
derived microvesicles (expressed as % share of spectrum IDs).
Bead HIV-1BaL (CD45+) Vesicles (activated) Vesicles (non-activated)
a-enolase 0.95 0.569 0.149
Pyruvate kinase 0.716 0.28 0.029
CD81 0.072 0.071 0.032
CD9 0.052 0.052 0.032
Actin/related proteins 0.39 0.063 0.028
doi:10.1371/journal.ppat.1003700.t003
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Dr. Lung-Ji Chang) plasmids using polyethylenimine (PEI,
Polyscience; Warrington, PA, USA) to generate VsV-g pseudo-
typed pBaL. Purified high titre HIV-1BaL stocks in the order
of 26109 TCID50/mL were generated by infection of
SUPT1.CCR5-CL.30 cells (Human Non-Hodgkin’s T lymphocyte
Lymphoma, contributed by Prof. James Hoxie at the University of
PA) with VsV-g pseudotyped pBaL. HIV-1 infected supernatants
were concentrated using tangential filter concentration using
the Millipore Lab scale system (Millipore; Billerica, MA, USA)
and 26Pellicon filters connected in parallel (300 kDa) (Millipore).
When required, CD45+ MVs were depleted from supernatant
using CD45 magnetic beads (Miltenyi Biotech). Virus (18 mLs)
was incubated at room temperature with 2 mLs microbeads
for 2 hours before adding to the top of a LS column. CD45
depleted virus that flowed through the column as well as non-
depleted supernatants were concentrated further by ultracentrifu-
gation with 1 mL under-layed 20% sucrose cushion and centri-
fuged at 100,0006g (Beckman Optima XL-100K Ultracentrifuge
with 70Ti rotor) at 4uC for 90 minutes. Virus content was
determined by p24 gag ELISA as per manufacturer’s instructions
(Beckman-Coulter; Hialeah, FL). The 50% tissue culture infectious
dose (TCID50) values were generated in TZM-BL cells (NIH
AIDS Research and Reference Reagent Program, contributed
by John Kappes and Xiaoyun Wu) measured by LTR b-
galactosidase reporter gene expression after a single round of
infection [75].
MVs from activated SUPT1.CCR5-CL.30 or primary T
lymphocytes were generated using antibodies to CD3 (1 mg/mL,
BD Pharmingen; Becton Dickinson; San Jose, CA) and CD28
(5 mg/mL, BD Pharmingen) added to 1006106 cells, cultured for
3 or 6 days respectively alongside unstimulated cells and the
supernatant concentrated as above. The CD45 concentration for
virus and MV was determined by western blot. Endotoxin levels
for all virus and MV stocks were negative using the ToxinSensor
Chromogenic LAL Endotoxin Assay Kit (GeneScript; Piscataway,
NJ).
MDDC Treatment with HIV-1, Microvesicles or
Recombinant Proteins
Immature day 5 MDDCs were infected with pelleted (HIV-
1BaL(pellet)) or CD45depleted (HIV-1BaL(CD45
2)) virus in 200 mL
media with a MOI of 3 at 37uC for 2 hours before resuspending at
16106/mL and incubating further as required. MVs were added
at 20 mL/mL to match the CD45 concentration to HIV-
1BaL(pellet) virus stocks. Recombinant proteins were added at
various final concentrations to MDDCs cultured at 0.56106cells/
mL in RF10+cytokines. Harvested cells at 48 hours post treatment
for FACS analysis.
Flow Cytometry
Direct conjugated mAbs directed against ICAM-1-fluorescein
isothiocyanate (FITC) (Beckman Coulter), CD80-Phycoerythrin-
Cy5 (PE-Cy5), CD83-FITC, CD86-PE-Cy5, HLA-DR-Allophy-
cocyanin (APC), MR-APC, CD1a-FITC, CD40-FITC, CD3-
APC, CD8-PE-Cy5 and CD69-APC (BD Pharmingen) and CD4-
PE (Sigma) were used for surface staining. Antibody staining was
performed at 4uC for 30 minutes using fluorescence-activated
cell sorter buffer (1% (v/v) Human Ab Serum, 2 mM EDTA and
0.1% (w/v) sodium azide made up in PBS). For intracellular
staining HIV-1BaL or mock treated MDDCs were fixed and
permeabilised in Cytofix/Cytoperm (BD), re-suspended in
permwash buffer (1% (v/v) human AB serum (Sigma), 0.1% (w/
v) saponin, 0.1% (w/v) sodium azide, made up in PBS at 4uC)
and incubated for 2 hours with PE conjugated p24 (clone KC57-
RD1, Beckman Coulter; Fullerton, CA). IgG isotype control
antibodies were incubated with cells to control for nonspecific
binding. Cells were then analysed with a FACS-Canto flow
cytometer (Becton Dickinson) and FlowJo (Tree Star Inc.,
Ashland, OR).
Blocking of ICAM-1 (clone HA58, 5 mg/26105 cells, BD
Pharmingen) was performed at 37uC for 30 minutes.
Q-PCR
26105 cells were lysed at 60uC for 90 minutes in Q-PCR Lysis
Buffer (10 mM Tris-Hydrochloride, 50 mM potassium chloride,
2.5 mM magnesium chloride, 0.45% (v/v) NP-40, 0.45% (v/v)
Tween-20, 50 mg/mL Proteinase K (Sigma)) followed by dena-
turing at 94uC for 15 minutes. HIV-1 proviral DNA was detected
using the HIV-long terminal repeat (LTR) gag primer probe set as
previously described [76]. The cell number was normalised to
albumin as previously described [77]. The HIV-1 assay reaction
contained Quantitative PCR SuperMix-UDG mastermix (Invitro-
gen), 300 nM forward primer, 300 nM reverse primer and 50 nM
dual labelled probe and the albumin assay contained 150 nM dual
labelled probe. After initial incubations of 50uC for 2 minutes and
94uC for 2 minutes, 45 cycles of amplification were carried out at
95uC for 15 seconds followed by 64uC for 45 seconds for the HIV-
1 assay and 62uC for 45 seconds for the Albumin assay. The
reaction run on the Corbett 3000 Rotor-Gene machine (Corbett
Life Science; Sydney, NSW, Aus) and analysed using Corbett
Rotor-Gene 6 software (version 6.0).
In addition, the expressions of selected genes were assessed
using reverse transcribed total unamplified RNA as previously
described [10]. The cDNA was subject to Q-PCR using published
primers [10] with the addition of ICAM-1 primers: (Forward:
CGTGGGGAGAAGGAGCTGAA, Reverse: CAGTGCGG-
CACGAGAAATTG, Sigma).
Table 4. Concentrations of heat shock proteins and HIV-1 Nef and Gag in HIV-1 inocula and of HSPs in uninfected SUPT1.CCR5-
CL.30 derived microvesicles (MVs).
HIV-1BaL (pellet) HIV-1BaL (CD452) MVs (activated) MVs (non-activated)
HSP90a 0.32 0.33 0.40 0.13
HSP90b 0.20 0.63 0.25 0.04
HSP70/71 0.03 0.00 0.00 0.00
HIV-1 nef 0.023 0.00
HIV-1 Gag 2.17 3.82
HIV-1 env 0.021 0.073
doi:10.1371/journal.ppat.1003700.t004
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Figure 8. Recombinant HSP90b and recombinant Nef induce MDDC maturation and ICAM-1 expression. MDDCs (0.56106 cells/mL)
were treated with recombinant proteins, A) HSP90b and B) nef at variable concentrations for 48 hours. The effects on the maturation markers, CD80,
CD83 and CD86, were measured by flow cytometry and expressed as log (2) fold change in MFI compared to mock treated MDDCs (mean +/2 SEM,
n = 3, *p,0.05, **p,0.01). C) MDDCs (0.56106 cells/mL) were treated with recombinant nef at 10 nM (lowest significant effective concentration) and
recombinant HSP90b at 0.5 nM (completely ineffective concentration on MDDC maturation alone) or maturation mix for 48 hours and expression of
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Functional Studies
For the clustering assay, treated MDDC were co-cultured with
autologous CD4+ T lymphocytes at a ratio of 1 DC:5 T
lymphocytes and incubated at 37uC for 45 minutes. Cells were
subsequently stained for CD1a, CD3 and p24 for flow cytometric
analysis as described above.
The proliferation was determined by carboxyfluroescein
succinimidyl ester (CFSE) dilution. Briefly, allogeneic PBMCs
CD80, CD83 and CD86 measured by flow cytometry and expressed as log (2) fold change in MFI compared to mock treatment (mean +/2 SEM, n= 3,
*p,0.05, **p,0.001).
doi:10.1371/journal.ppat.1003700.g008
Figure 9. A model of HIV-1 induced and bystander effects on MDDCs. Diagram of MDDCs infected with either A) HIV-1BaL(pellet) or B) HIV-
1BaL(CD45
2) virus. MDDCs exposed to HIV-1BaL(pellet) had increased maturation, limited infection and when co-cultured with T lymphocytes, T
lymphocyte activation and HIV-1 transfer was observed. When the MDDCs were assessed based on their p24 status to delineate between infected
(p24+) and uninfected bystanders (p242), there were notable differences with infected MDDCs showing greater maturation, ICAM-1 expression and
clustering. However, as only 1–2% of the population were considered infected, T lymphocytes activated by bystander MDDC interactions could also
then interact with the small infected population resulting in HIV-1 transfer to these cells. In contrast, MDDCs exposed to the HIV-1BaL(CD45
2) had
limited MDDC maturation and increased HIV-1 infection. The infected MDDCs did show some maturation, ICAM-1 expression and clustering to T
lymphocytes, whereas the bystander cells did not. When co-cultured with T lymphocytes, little T lymphocyte activation and HIV-1 transfer was
observed, possibly due to a small number of exposed MDDCs able to activate the T lymphocytes (5–10%) compared to the majority of MDDCs when
exposed to HIV-1BaL(pellet). The differences seen between the two virus stocks were a due to the presence of MV in the HIV-1BaL(pellet) virus. up
arrow=up-regulated compared to mock, down arrow=down-regulated compared to mock and left-right arrow=no change compared to mock.
doi:10.1371/journal.ppat.1003700.g009
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were stained with 5 mM final concentration CSFE (Molecular
Probes; Eugene, OR) for 10 minutes at 37uC, rescued with equal
volume of 100% FBS and washed with RPMI+10% FBS. These
PBMCs were added to the HIV-1BaL infected MDDCs at a ratio of
1 MDDC:10 PBMC and incubated at 37uC for 5 days. Cells were
subsequently stained for CD3, CD4, CD8 and p24 for flow
cytometric analysis as described above.
Transfer of HIV-1 from DCs to T Lymphocytes
MDDCs infected with HIV-1BaL (pellet or CD45
2) for 48 hours
were co-cultured with resting CD4+ T lymphocytes for a further
24, 48, 72, 96 and 120 hours at 37uC before staining with p24
antibody for flow cytometry as described above.
Western Blot and Tangential Mass Spectrometry Analysis
of Preparations
Viral, MV and parent cell preparations were lysed for 1 hour at
4uC in SDS lysis buffer (10 mM HEPES, 150 mM NaCl, 1% (v/v)
Triton-X-100, 1 mg/mL protease inhibitor cocktail (Sigma) at pH
of 7.5), followed by centrifugation for 10 minutes at 16,0006g at
4uC. The protein concentration was determined using the DC
Protein Assay (Bio-Rad) according to the manufacturer’s instruc-
tions. The protein concentration was determined using the DC
Protein Assay (Bio-Rad) according to the manufacturer’s instruc-
tions.
30 mg of protein prepared with 16NUPAGE lithium dodecyl
sulfate (LDS) sample buffer (Invitrogen) containing 400 mM
dithiothreitol was boiled for 10 minutes before loaded into
NUPAGE 4–12% polyacrylamide bis-tris gradient SDS-PAGE
gels (Invitrogen) alongside a 10–250 kilo Dalton (kDa) molecular
weight marker (Bio-Rad). Electrophoresis was run at 200 V for
50 minutes in NUPAGE 3-(N-morpholino)propanesulfonic acid
(MOPS) SDS Running Buffer (Invitrogen). The proteins were
transferred to a nitrocellulose membrane (Amersham Biosciences)
in transfer buffer (250 mM Tris (pH 8.3), 1.92M Glycine and
0.05% (w/v) SDS) overnight at 55 mA. Non-specific binding sites
were blocked by incubating for 1 hour in 250 mM Tris (pH 8),
1.4M NaCl and 30 mM KCl (pH 8) containing 20% (v/v)
polyethylene glycol tert-octylphenyl ether and 5% skim milk). Blots
were incubated with the primary antibodies in 1% skim milk
solution followed by the appropriate peroxidase conjugated
secondary antibody (Cell Signaling). Primary antibodies were:
CD45 (clone 69/CD45, BD Transduction labs), exosome markers:
Alix (3A9, Biolegend), CD9 (EPR2949, Abcam), CD81 (JS-81, BD
Pharmingen), SMV markers: CD11a (HI111, Biolegend), CD40
(polyclonal, Abcam), AB markers: H2A (poly 6194) and H3
(poly6019, Biolegend) and maturation stimuli markers: CD40L
(polyclonal, Abcam), TNF-a (Mab1, Biolegend), HSP60 (poly-
clonal), HSP70 (3C6), HSP90AB1 (4C10) and HSP90B1
(EPR3988, Origene). The membrane was developed using
Western Lighting Enhanced Chemiluminescence Substrate Re-
agent and the Oxidising Reagent (Perkin Elmer; Glen Waverly,
Vic, Aus).
For Mass Spectrometry, 30 mg of each sample was prepared in
SDS lysis buffer, run on 4–12% bis-tris gradient SDS-PAGE gel
and stained with Brilliant Blue G (Sigma).
The 1D SDS-Gel lanes were sliced into 31 1 mm65 mm bands
using a disposable grid cutter (The Gel Company, USA) and in-gel
digested with trypsin using an automated liquid handling
procedure with a TECAN Freedom Evo liquid handling system
(Ma¨nnedorf, Switzerland). The 31 fractions were pooled (2 gel
fractions per pool) and analysed by LC-MS/MS in duplicate.
Peptide separation was performed on an Eksigent Nano 2D plus
system (ABSciex, USA) employing splitless pumps enabled for
nanoflow rates. RP-HPLC Trap and separation columns were
prepared in-house (Supplementary data for extended Materials
and Methods). For each LC run, sample was injected on the trap
and washed for 10 minutes at 2.5 mL/min with loading buffer (2%
v/v acetonitrile and 0.1% v/v Formic acid). Sample was separated
by a linear gradient changing from 97% A (0.1% v/v formic acid
in water) and 2% B (0.1% v/v formic acid in acetonitrile) to 40%
A and 60% B in 60 minutes at 0.3 mL/min. The in-gel digested
samples were analysed with a Thermo-Fisher LTQ-Velos Orbi-
trap. MS1 data were collected over the range of 300–2000 m/z in
the Orbitrap set at resolution 30,000. FTMS preview scan and
predictive automatic gain control (pAGC) were enabled. The full
scan FTMS target ion volume was 16106 with a max fill time of
500 ms. MS2 data were collected in the LTQ-Velos with a target
ion volume of 16104 and a max fill time of 100 ms. The 20 most
intense peaks from a preview scan of each full Orbitrap scan were
selected (with a selection window of 2.0 Da) for collision-induced
dissociation (CID) with wide-band activation. Dynamic exclusion
was enabled to exclude an observed precursor for 180 seconds
after two observations. The dynamic exclusion list size was set at
the maximum 500 and the exclusion width was set at 65 ppm
based on precursor mass. Monoisotopic precursor selection and
charge state rejection were enabled to reject precursors with z =+1
or unassigned charge state.
Mass Spectrometry analysis involved converting Thermo .RAW
files to mzXML format using MSConvert [78] and searched with
X!Tandem [79] version 2010.10.01.1 (Supplementary data for
extended Materials and Methods).
The identified peptides and their inferred proteins and spectral
quantities are reported in the appended Microsoft Excel file
(Mercier et al peptide-protein proteomic data.xlsx). The raw data
for this project (103 Thermo .raw files, 53.5 Gb total) has been
deposited in the Tranche proteomics raw data repository [80,81]
and may be downloaded from the Peptide Atlas data repository
http://www.peptideatlas.org/PASS/PASS00251 or the Proteo-
meCommons.org Tranche repository using the following hash:
‘‘69iC+dKFUFu7JMcZxCSdI3cS0q37GPeG3yuWB2h32wnh27
xemcTBoEY75tDGOGt0fGFes8Jyxf+ST5lv7Uz7lfUY5UQAA
AAAAAAy3A== ’’
Supplementary Information
The raw data for this project (103 Thermo .raw files, 53.5 Gb
total) has been deposited in the Tranche proteomics raw data
repository [6,7] and may be downloaded from the PeptideAtlas
data repository
http://www.peptideatlas.org/PASS/PASS00251 or the Proteo-
meCommons.org
Tranche repository using the following hash:
‘‘69iC+dKFUFu7JMcZxCSdI3cS0q37GPeG3yuWB2h32wnh
27xemcTBoEY75tDGOGt0fGFes8Jy 69iC+xf+ST5lv7Uz7lfUY
5UQAAAAAAAAy3A== ’’
Supporting Information
Figure S1 SAMHD1 expression in MV treated maturing
MDDCs. MDDCs (0.56106/ml) were treated or mock treated
with MVs from activated or non-activated primary CD4+
lymphocytes as in Figure 3D and lysates were processed for
western blot as in Figure 7A, using antibodies to SAMHD1
(Abcam) and GAPDH.
(EPS)
Figure S2 Recombinant HSP90a also induces matura-
tion of MDDCs. MDDCs (0.56106/ml) were treated with
variable concentrations of recombinant HSP90a (similar to
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HSP90b) as in figure 7B and expression of maturation markers
CD80, 83 and 86, MR and DC-SIGN measured by flow
cytometry and expressed as log2fold change in MFI compared
to mock treatment. (Mean +/2 SE, n= 3, *p,0.05).
(EPS)
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